Table 6.
Parameters | Treatments |
SEM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Control | A10 | A20 | A30 | A40 | A50 | ALN10 | ALN20 | ALN30 | ALN40 | ALN50 | ||
GPx (U/mg protein) | 53.2c | 55.3b,c | 57.5b | 60.2a,b | 57.2a,b | 51.1c | 56.3b | 60.0a,b | 64.8a | 58.1a,b | 52.9c | 1.8 |
SOD (U/mg) | 106.2 | 108.2 | 112.3 | 114.5 | 107.3 | 104.4 | 109.6 | 113.2 | 116.7 | 112.3 | 106.8 | 8.4 |
TAC (mmol/l) | 1.2c,d | 1.3b,c,d | 1.4b,c | 1.7a,b | 1.4b,c | 1.0d | 1.3b,c,d | 1.6a,b | 1.8a | 1.5a,b,c | 1.3b,c,d | 0.1 |
Different superscripts within the same row indicate significant differences among groups (P < 0.05).
Extender supplemented with different levels of alpha-lipoic acid containing 10 (A10), 20 (A20), 30 (A30), 40 (A40) and 50 (A50) μM and alpha-lipoic acid loaded nanostructured lipid carriers (ALN) containing 10 (ALN10), 20 (ALN20), 30 (ALN30), 40 (ALN40) and 50 (ALN50) μM.